{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:09:38Z","timestamp":1792660178941,"version":"4.5.0"},"reference-count":58,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1097\/spc.0000000000000086","type":"journal-article","created":{"date-parts":[[2014,8,10]],"date-time":"2014-08-10T13:48:03Z","timestamp":1407678483000},"page":"328-333","source":"Crossref","is-referenced-by-count":6,"title":["Immunomodulatory agents for the treatment of cachexia"],"prefix":"10.1097","volume":"8","author":[{"given":"Martin","family":"Chasen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Bhargava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalom","family":"Hirschman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20211004","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ctrv.2012.08.003","article-title":"The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer.","volume":"39","author":"McMillan","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"R2-4-20211004","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/bjc.2014.90","article-title":"Cancer and systemic inflammation: treat the tumour and treat the host.","volume":"110","author":"Roxburgh","year":"2014","journal-title":"Br J Cancer"},{"key":"R3-4-20211004","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3747\/co.v17i4.567","article-title":"The predictive value of pretreatment inflammatory markers in advanced nonsmall-cell lung cancer.","volume":"17","author":"Kasymjanova","year":"2010","journal-title":"Curr Oncol"},{"key":"R4-4-20211004","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1152\/physrev.00016.2008","article-title":"Mechanisms of cancer cachexia.","volume":"89","author":"Tisdale","year":"2009","journal-title":"Physiol Rev"},{"key":"R5-4-20211004","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1155\/2013\/171437","article-title":"TNF- and IFN-s-dependent muscle decay is linked to NF-B- and STAT-1-stimulated Atrogin1 and MuRF1 genes in C2C12 Myotubes.","volume":"2013","author":"Pijet","year":"2013","journal-title":"Mediators Inflamm"},{"key":"R6-4-20211004","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/MOG.0b013e3283347e77","article-title":"Cancer cachexia.","volume":"26","author":"Tisdale","year":"2010","journal-title":"Curr Opin Gastroenterol"},{"key":"R7-4-20211004","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nrd3800","article-title":"Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases.","volume":"11","author":"Dinarello","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"R8-4-20211004","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2012.06.011","article-title":"Cancer cachexia: mediators, signaling, and metabolic pathways.","volume":"16","author":"Fearon","year":"2012","journal-title":"Cell Metab"},{"key":"R9-4-20211004","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1016\/S1470-2045(12)70582-X","article-title":"Cytokine patterns in patients with cancer: a systematic review.","volume":"14","author":"Lippitz","year":"2013","journal-title":"Lancet Oncol"},{"key":"R10-4-20211004","first-page":"295","article-title":"Growth differentiating factor-15 (GDF-15) induces anorexia and cachexia in mice: a novel pathway for cachexia.","volume":"4","author":"Lerner","year":"2013","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R11-4-20211004","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s13539-011-0035-5","article-title":"The role of myostatin in muscle wasting: an overview.","volume":"2","author":"Elkina","year":"2011","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R12-4-20211004","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.critrevonc.2013.03.010","article-title":"The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer.","volume":"88","author":"Guthrie","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"R13-4-20211004","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2217\/fon.09.136","article-title":"Role of systemic inflammatory response in predicting survival in patients with primary operable cancer.","volume":"6","author":"Roxburgh","year":"2010","journal-title":"Future Oncol"},{"key":"R14-4-20211004","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus.","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol"},{"key":"R15-4-20211004","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/bjc.2013.701","article-title":"Molecular diagnostics. Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients.","volume":"110","author":"Szkandera","year":"2014","journal-title":"Br J Cancer"},{"key":"R16-4-20211004","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.ejca.2012.09.004","article-title":"The value of C-reactive protein and comorbidity in predicting survival of patients with high grade soft tissue sarcoma.","volume":"49","author":"Nakamura","year":"2013","journal-title":"Eur J Cancer"},{"key":"R17-4-20211004","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3109\/10408363.2011.599831","article-title":"Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer.","volume":"48","author":"Allin","year":"2011","journal-title":"Crit Rev Clin Lab Sci"},{"key":"R18-4-20211004","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1128\/CVI.00636-12","article-title":"Targeting the cytokine storm for therapeutic benefit.","volume":"20","author":"DElia","year":"2013","journal-title":"Clin Vaccine Immunol"},{"key":"R19-4-20211004","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.clnu.2008.06.013","article-title":"Cachexia: a new definition.","volume":"27","author":"Evans","year":"2008","journal-title":"Clin Nutr"},{"key":"R20-4-20211004","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group.","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"R21-4-20211004","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S0885-3924(02)00502-X","article-title":"Physical function in patients with cancer: psychometric characteristics and clinical usefulness of a physical performance test battery.","volume":"24","author":"Simmonds","year":"2002","journal-title":"J Pain Symptom Manage"},{"key":"R22-4-20211004","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/ptj\/82.2.128","article-title":"Age- and gender-related test performance in community-dwelling elderly people: Six-Minute Walk Test, Berg Balance Scale, Timed Up and Go Test, and gait speeds.","volume":"82","author":"Steffen","year":"2002","journal-title":"Phys Ther"},{"key":"R23-4-20211004","first-page":"8","article-title":"PGSGA Patient-generated subjective global assessment of nutritional status.","volume":"2","author":"Ottery","year":"1996","journal-title":"Nutritional Oncol"},{"key":"R24-4-20211004","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1002\/1097-0142(20001001)89:7<1634::AID-CNCR29>3.0.CO;2-V","article-title":"Assessing symptom distress in cancer patients: the MD Anderson Symptom Inventory.","volume":"89","author":"Cleeland","year":"2000","journal-title":"Cancer"},{"key":"R25-4-20211004","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"R26-4-20211004","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1177\/082585979100700202","article-title":"The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients.","volume":"7","author":"Bruera","year":"1991","journal-title":"J Palliat Care"},{"key":"R27-4-20211004","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/0277-5379(89)90353-2","article-title":"Effect of methylprednisolone sodium succinate on quality of life in preterminal cancer patients: a placebo-controlled, multicenter study. The Methylprednisolone Preterminal Cancer Study Group.","volume":"25","author":"Della Cuna","year":"1989","journal-title":"Eur J Cancer Clin Oncol"},{"key":"R28-4-20211004","first-page":"751","article-title":"Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study.","volume":"69","author":"Bruera","year":"1985","journal-title":"Cancer Treat Rep"},{"key":"R29-4-20211004","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1136\/bmj.288.6410.27","article-title":"Prednisolone as an appetite stimulant in patients with cancer.","volume":"288","author":"Willox","year":"1984","journal-title":"Br Med J (Clin Res Ed)"},{"key":"R30-4-20211004","first-page":"CD008664","article-title":"Thalidomide for managing cancer cachexia.","volume":"4","author":"Reid","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"R31-4-20211004","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00520-002-0408-6","article-title":"The cancer cachectic factor.","volume":"11","author":"Tisdale","year":"2003","journal-title":"Support Care Cancer"},{"key":"R32-4-20211004","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1136\/gut.52.10.1479","article-title":"Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomized double blind trial.","volume":"52","author":"Fearon","year":"2003","journal-title":"Gut"},{"key":"R33-4-20211004","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/jnci\/djt174","article-title":"Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial.","volume":"105","author":"Brasky","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"R34-4-20211004","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1200\/JCO.2004.06.024","article-title":"An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute Canada collaborative effort.","volume":"22","author":"Jatoi","year":"2004","journal-title":"J Clin Oncol"},{"key":"R35-4-20211004","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1200\/JCO.2003.01.101","article-title":"Effect of fish oil on appetite and other symptoms in patients with advanced cancer and anorexiacachexia: a double-blind, placebo-controlled study.","volume":"21","author":"Bruera","year":"2003","journal-title":"J Clin Oncol"},{"key":"R36-4-20211004","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.clnu.2011.10.005","article-title":"Randomized phase III clinical trial of a combined treatment with carnitine celecoxib megestrol acetate for patients with cancer-related anorexiacachexia syndrome.","volume":"31","author":"Madeddu","year":"2011","journal-title":"Clin Nutr Epub"},{"key":"R37-4-20211004","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/S0140-6736(11)61720-0","article-title":"Short-term effects of daily aspirin on cancer incidence, mortality, and nonvascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials.","volume":"379","author":"Rothwell","year":"2012","journal-title":"Lancet"},{"key":"R38-4-20211004","first-page":"505","article-title":"Evidence that long-term COX-treatment improves energy homeostasis and body composition in cancer patients with progressive cachexia.","volume":"24","author":"Lundholm","year":"2004","journal-title":"Int J Oncol"},{"key":"R39-4-20211004","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3109\/0284186X.2012.724536","article-title":"Nonsteroidal antiinfl ammatory treatment in cancer cachexia: a systematic literature.","volume":"52","author":"Solheim","year":"2013","journal-title":"Acta Oncologica"},{"key":"R40-4-20211004","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1016\/j.jacc.2014.01.054","article-title":"Innate and adaptive inflammation as a therapeutic target in vascular disease: the emerging role of statins.","volume":"63","author":"Tousoulis","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R41-4-20211004","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1093\/jnci\/djr307","article-title":"Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803.","volume":"103","author":"Ng","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"R42-4-20211004","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/jco.2010.28.15_suppl.7622","article-title":"Effect of ALD518, a humanized anti-IL-6 antibody, on lean body mass loss and symptoms in patients with advanced nonsmall cell lung cancer (NSCLC): results of a phase II randomized, double-blind safety and efficacy trial.","volume":"28","author":"Rigas","year":"2010","journal-title":"J Clin Oncol"},{"key":"R43-4-20211004","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1002\/cncr.22944","article-title":"A placebo-controlled double blind trial of etanercept for the cancer anorexiaweight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group.","volume":"110","author":"Jatoi","year":"2007","journal-title":"Cancer"},{"key":"R44-4-20211004","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1517\/14712598.2011.627850","article-title":"A humanized anti-IL-6 antibody (ALD518) in nonsmall cell lung cancer.","volume":"11","author":"Bayliss","year":"2011","journal-title":"Expert Opin Biol Ther"},{"key":"R45-4-20211004","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jamda.2010.02.012","article-title":"Phase II study of the novel peptide-nucleic acid OHR118 in the management of cancer-related anorexiacachexia.","volume":"12","author":"Chasen","year":"2011","journal-title":"J Am Med Dir Assoc"},{"key":"R46-4-20211004","first-page":"335","article-title":"Phase II study of OHRAVR 118 in anorexia-cachexia.","volume":"4","author":"Chasen","year":"2013","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R47-4-20211004","first-page":"295","article-title":"Growth differentiating factor-15 (GDF-15) induces anorexia and cachexia in mice: a novel pathway for cachexia.","volume":"4","author":"Lerner","year":"2013","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R48-4-20211004","doi-asserted-by":"crossref","first-page":"e55174","DOI":"10.1371\/journal.pone.0055174","article-title":"TGF-b superfamily cytokine MIC-1GDF15 is a physiological appetite and body weight regulator.","volume":"8","author":"Tsai","year":"2013","journal-title":"PLoS One"},{"key":"R49-4-20211004","first-page":"295","article-title":"USP19 regulates differentiation of muscle cells.","volume":"4","author":"Wiles","year":"2013","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R50-4-20211004","first-page":"295","article-title":"Identification and characterization of USP19 inhibitors.","volume":"4","author":"Segawa","year":"2013","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R51-4-20211004","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s13539-012-0096-0","article-title":"Cancer cachexia prevention via physical exercise: molecular mechanisms.","volume":"4","author":"Gould","year":"2013","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R52-4-20211004","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nri3041","article-title":"The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease.","volume":"11","author":"Gleeson","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"R54-4-20211004","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.jamda.2013.04.008","article-title":"New strategies for the concurrent strength-, power-, and endurance-training prescription in elderly individuals.","volume":"14","author":"Cadone Cadore","year":"2013","journal-title":"J Am Med Dir Assoc"},{"key":"R56-4-20211004","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jamda.2013.05.021","article-title":"Evidence-based recommendations for optimal dietary protein intake in older people: a position paper from the PROT-AGE study group.","volume":"14","author":"Bauer","year":"2013","journal-title":"J Am Med Dir Assoc"},{"key":"R57-4-20211004","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jamda.2012.07.005","article-title":"Protein supplementation improves physical performance in frail elderly people: a randomized, double-blind, placebo-controlled trial.","volume":"13","author":"Tieland","year":"2012","journal-title":"J Am Med Dir Assoc"},{"key":"R58-4-20211004","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3747\/co.20.1607","article-title":"Pereira results of an interprofessional palliative care oncology rehabilitation program.","volume":"20","author":"Chasen","year":"2013","journal-title":"Curr Oncol"},{"key":"R59-4-20211004","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3747\/co.20.1612","article-title":"An interdisciplinary nutrition-rehabilitation program for patients with advanced cancer.","volume":"20","author":"Gagnon","year":"2013","journal-title":"Curr Oncol"},{"key":"R61-4-20211004","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3747\/co.20.1854","article-title":"Multimodal cancer care research.","volume":"20","author":"MacDonald","year":"2013","journal-title":"Curr Oncol"}],"container-title":["Current Opinion in Supportive &amp; Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/01263393-201412000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T03:53:25Z","timestamp":1746330805000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01263393-201412000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":58,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/spc.0000000000000086","relation":{},"ISSN":["1751-4258"],"issn-type":[{"value":"1751-4258","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]}}}